Merck MKGAF Stock
Merck Price Chart
Merck MKGAF Financial and Trading Overview
| Merck stock price | 167.06 USD |
| Previous Close | 158.72 USD |
| Open | 161.82 USD |
| Bid | 158 USD x 30000 |
| Ask | 168.07 USD x 10000 |
| Day's Range | 161.82 - 161.82 USD |
| 52 Week Range | 116.68 - 175.56 USD |
| Volume | 57 USD |
| Avg. Volume | 664 USD |
| Market Cap | 72.64B USD |
| Beta (5Y Monthly) | 0.785 |
| PE Ratio (TTM) | 26.267767 |
| EPS (TTM) | 6.36 USD |
| Forward Dividend & Yield | 2.58 (1.61%) |
| Ex-Dividend Date | April 27, 2026 |
| 1y Target Est | N/A |
MKGAF Valuation Measures
| Enterprise Value | 81.74B USD |
| Trailing P/E | 26.267767 |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | 2.28 |
| Price/Sales (ttm) | 3.4367306 |
| Price/Book (mrq) | 2.137242 |
| Enterprise Value/Revenue | 3.867 |
| Enterprise Value/EBITDA | 14.63 |
Trading Information
Merck Stock Price History
| Beta (5Y Monthly) | 0.785 |
| 52-Week Change | 20.83% |
| S&P500 52-Week Change | 12.38% |
| 52 Week High | 175.56 USD |
| 52 Week Low | 116.68 USD |
| 50-Day Moving Average | 159.19 USD |
| 200-Day Moving Average | 150.88 USD |
MKGAF Share Statistics
| Avg. Volume (3 month) | 664 USD |
| Avg. Daily Volume (10-Days) | 260 USD |
| Shares Outstanding | 129.24M |
| Float | 128.86M |
| Short Ratio | N/A |
| % Held by Insiders | 0% |
| % Held by Institutions | 58.62% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 2.2 |
| Trailing Annual Dividend Yield | 1.38% |
| 5 Year Average Dividend Yield | 131.00% |
| Payout Ratio | 0.4037 |
| Last Split Factor | 2:1 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 11.21% |
| Operating Margin (ttm) | 13.85% |
| Gross Margin | 59.08% |
| EBITDA Margin | 26.43% |
Management Effectiveness
| Return on Assets (ttm) | 4.65% |
| Return on Equity (ttm) | 8.13% |
Income Statement
| Revenue (ttm) | 21.13B USD |
| Revenue Per Share (ttm) | 48.63 USD |
| Quarterly Revenue Growth (yoy) | 3.40% |
| Gross Profit (ttm) | 12.49B USD |
| EBITDA | 5.59B USD |
| Net Income Avi to Common (ttm) | 2.37B USD |
| Diluted EPS (ttm) | 6.36 |
| Quarterly Earnings Growth (yoy) | -24.80% |
Balance Sheet
| Total Cash (mrq) | 3.12B USD |
| Total Cash Per Share (mrq) | 7.2 USD |
| Total Debt (mrq) | 12.3B USD |
| Total Debt/Equity (mrq) | 40.62 USD |
| Current Ratio (mrq) | 1.695 |
| Book Value Per Share (mrq) | 78.167564 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 4.23B USD |
| Levered Free Cash Flow (ttm) | 2.63B USD |
Profile of Merck
| Country | United States |
| State | N/A |
| City | Darmstadt |
| Address | Frankfurter Strasse 250 |
| ZIP | 64293 |
| Phone | 49 6151 72 0 |
| Website | https://www.merckgroup.com |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 62136 |
Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry kits and instruments. This segment also provides traditional and novel therapies, such as ration devices, chromatography resins, single-use systems, process chemicals, and excipients for bioprocessing; contract development, manufacturing and testing services, which supports customers from preclinical phases to commercialization. The Healthcare segment discovers, develops, manufactures, and markets prescription drugs and biopharmaceuticals to the therapeutic areas of oncology, rare diseases, neurology and immunology, fertility, cardiovascular, and metabolic and endocrinological disorders. The Electronics segment offers advanced dielectric and metallic materials; photoresist, anti-reflective coating, and material lithography products; clean and selective etch chemistries; materials for chemical-mechanical planarization; high-purity gases for semiconductor manufacturing; and develops and installs delivery equipment for handling of specialty chemicals and gases for semiconductor manufacturing; develops modulating, creating, engineering, and guiding light; and material solutions in liquid crystals, OLED materials, and photoresists. It has in-licensing agreement with Abbisko Therapeutics Co. Ltd., China on drug candidates for the treatment of tenosynovial giant cell tumor; and strategic partnership with Versant Ventures to advance treatments for rare genetic cardiomyopathies. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.
Q&A For Merck Stock
What is a current MKGAF stock price?
Merck MKGAF stock price today per share is 167.06 USD.
How to purchase Merck stock?
You can buy MKGAF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Merck?
The stock symbol or ticker of Merck is MKGAF.
Which industry does the Merck company belong to?
The Merck industry is Drug Manufacturers - Specialty & Generic.
How many shares does Merck have in circulation?
The max supply of Merck shares is 434.78M.
What is Merck Price to Earnings Ratio (PE Ratio)?
Merck PE Ratio is 26.26776700 now.
What was Merck earnings per share over the trailing 12 months (TTM)?
Merck EPS is 6.36 USD over the trailing 12 months.
Which sector does the Merck company belong to?
The Merck sector is Healthcare.
